RE:RE:RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsThe global sales for migraine drugs have been valued at $4.6 billion in 2020 with a CAGR of more than 9%. The new classes of drugs that are in late-stage pipeline and have higher clinical efficacy, such as the introduction of calcitonin gene-related peptide (CGRP) monoclonal antibodies that have been the focus for Biohaven, are also driving the market growth which could reach USD$11 Billion by 2029. CGRP-targeted drugs, could account for more than $6.5 billion of sales in 2027.
Now compare the projected global market size to the cancer market. The global cancer therapeutics market size is projected to reach around US$ 335.06 billion by 2029. The cancer market is expected to be approximately 30x greater than the size of the global migraine market.
Meanwhile PD-1/PD-L1 checkpoint inhibitors have been significantly outperforming the global oncology market, growing at 5-year CAGR of 45%, or three times the rate of oncology overall, and are expected to reach $58 billion globally by 2025. The important fact accompanying the USD$ 58 Billion projection is that this value only considers the PD-1/PD-L1 checkpoint inhibitors used as a monotherapy and therefore effective in only 15-20% of the patients used. Combination with ONCY pelareorep is anticipated to increase the effectiveness of these checkpoint inhibitors by 2-3X thereby increasing the above expectation to between USD$ 116 Billion to USD$ 168 Billion by 2029, thus increasing the overall cancer therapeutics market size to around USD$ 503 Billion (335b+168b) by 2029 instead of the above projected USD $335.06 Billion figure.
This notwithstanding Pfizer announced the acquisition of Biohaven for USD$11.6 Billion ... so I would suggest that ONCY's acquisition value would fall into the USD$ 8 to USD$15 Billion range quite nicely